CommercialAdministrativeMedium impact
[New York] Lenalidomide is now available with end‑to‑end REMS support
Anthem BCBS·NY · Oncology, Hematology·Provider Bulletin
Effective date
May 1, 2026
We identified it
May 3, 2026
Summary
Lenalidomide is now available through BioPlus Specialty Pharmacy with end-to-end REMS (Risk Evaluation and Mitigation Strategies) management for New York commercial plans. BioPlus handles the full REMS process and prior authorization workflow, streamlining therapy initiation and reducing administrative burden on oncology practices.
Action Required
By May 1, 2026: Oncology and hematology providers must update referral and prescription workflows to direct lenalidomide patients to BioPlus Specialty Pharmacy (NCPDP 1078535, Fax: 800-269-5493, bioplusrx.com). Update clinical staff and billing team protocols to recognize that BioPlus manages end-to-end REMS compliance and prior authorization processing. Staff should use Availity Chat with Payer during business hours for eligibility, benefits, authorization, and claims status inquiries. No internal REMS coordination or prior authorization submissions are required from the practice. Update patient education materials to reference BioPlus as the specialty pharmacy vendor. Failure to route prescriptions through BioPlus may delay patient access and complicate REMS documentation.